QUOTE AND NEWS
Motley Fool  Dec 17  Comment 
MannKind may be on the precipice of growth surge thanks to Afrezza, but these three biotech stocks are still growing faster than MannKind.
Motley Fool  Dec 12  Comment 
MannKind's marketing partner, Sanofi, may be in big trouble.
SeekingAlpha  Dec 5  Comment 
FiercePharma  Nov 26  Comment 
The crowd is already assembling to watch Sanofi's upcoming rollout of Afrezza, the inhaled insulin developed by MannKind.
Motley Fool  Nov 26  Comment 
MannKind marketing partner Sanofi had to discount its Lantus insulin to get insurers to cover the drug.
Motley Fool  Nov 25  Comment 
Three Motley Fool analysts give their thoughts on whether or not to buy Al Mann's Second Sight on its initial public offering.




 

MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.

Business & Financial Metrics[1]

In 2009, MannKind incurred a net loss of $220.1 million and reported no revenue. This represents a 27.4% reduction in net loss from 2008, when the company lost $303.0 million. Since its inception in 1991, MannKind has lost $1.60 billion and generated $3.0 million in revenues.

Competition

MannKind's primary competitors include:

References

  1. MNKD 2009 10-K pg. 64  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki